T. Rowe Price Investment Management Reports New 9.5% Stake in Avalo Therapeutics (AVTX)

On May 15, 2026, T. Rowe Price Investment Management, Inc. filed a Schedule 13G with the SEC, reporting a new significant ownership stake in Avalo Therapeutics, Inc. (AVTX). As of the event date on March 31, 2026, the investment management firm reported beneficial ownership of 2,162,684 shares of common stock, representing a 9.5% ownership interest in the company. This filing indicates a substantial increase from a previous 0.0% position, marking a new major holding for the filer. T. Rowe Price Investment Management exercises sole voting and dispositive power over all 2,162,684 shares. The securities were acquired in the ordinary course of business and are not held for the purpose of changing or influencing the control of the issuer. The filing was signed by Ellen York, Vice President of T. Rowe Price Investment Management, Inc. The issuer is headquartered in San Francisco, California, and the filer is based in Baltimore, Maryland.